Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1478-6354
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study ; volume:16 ; number:4 ; day:8 ; month:7 ; year:2014 ; pages:1-10 ; date:8.2014
Arthritis Research & Therapy ; 16, Heft 4 (8.7.2014), 1-10, 8.2014
- Urheber
-
Fraticelli, Paolo
- Beteiligte Personen und Organisationen
-
Gabrielli, Barbara
Pomponio, Giovanni
Valentini, Gabriele
Bosello, Silvia
Riboldi, Piersandro
Gerosa, Maria
Faggioli, Paola
Giacomelli, Roberto
Del Papa, Nicoletta
Gerli, Roberto
Lunardi, Claudio
Bombardieri, Stefano
Malorni, Walter
Corvetta, Angelo
Moroncini, Gianluca
Gabrielli, Armando
SpringerLink (Online service)
- DOI
-
10.1186/ar4606
- URN
-
urn:nbn:de:1111-20160519685
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 08:22 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Fraticelli, Paolo
- Gabrielli, Barbara
- Pomponio, Giovanni
- Valentini, Gabriele
- Bosello, Silvia
- Riboldi, Piersandro
- Gerosa, Maria
- Faggioli, Paola
- Giacomelli, Roberto
- Del Papa, Nicoletta
- Gerli, Roberto
- Lunardi, Claudio
- Bombardieri, Stefano
- Malorni, Walter
- Corvetta, Angelo
- Moroncini, Gianluca
- Gabrielli, Armando
- SpringerLink (Online service)
Ähnliche Objekte (12)
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
High- and low-dose cyclophosphamide in Egyptian lupus nephritis patients: a multicenter retrospective analysis
Serpina3n/serpina3 alleviates cyclophosphamide-induced interstitial cystitis by activating the Wnt/β-catenin signal
Pathogenesis of interstitial lung disease in systemic sclerosis
Environmental Fate of Selected Anticancer Drugs: Photodegradation, Biodegradation and Toxicity of Cyclophosphamide, 5-Fluorouracil, Methotrexate and Imatinib
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report
Langerhans Cell Histiocytosis with Good Response to Low-Dose Imatinib: Case Report and Literature Review
Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
High- and low-dose cyclophosphamide in Egyptian lupus nephritis patients: a multicenter retrospective analysis
Serpina3n/serpina3 alleviates cyclophosphamide-induced interstitial cystitis by activating the Wnt/β-catenin signal
Pathogenesis of interstitial lung disease in systemic sclerosis
Environmental Fate of Selected Anticancer Drugs: Photodegradation, Biodegradation and Toxicity of Cyclophosphamide, 5-Fluorouracil, Methotrexate and Imatinib
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report
Langerhans Cell Histiocytosis with Good Response to Low-Dose Imatinib: Case Report and Literature Review
Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma
Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function
Benefit of Continuation of Low-Dose Imatinib for Gastrointestinal Stromal Tumors despite Adverse Events with Regular-Dose Imatinib
High- and low-dose cyclophosphamide in Egyptian lupus nephritis patients: a multicenter retrospective analysis
Serpina3n/serpina3 alleviates cyclophosphamide-induced interstitial cystitis by activating the Wnt/β-catenin signal
Pathogenesis of interstitial lung disease in systemic sclerosis
Environmental Fate of Selected Anticancer Drugs: Photodegradation, Biodegradation and Toxicity of Cyclophosphamide, 5-Fluorouracil, Methotrexate and Imatinib
Successful treatment of gemcitabine-induced acute interstitial pneumonia with imatinib mesylate: a case report
Langerhans Cell Histiocytosis with Good Response to Low-Dose Imatinib: Case Report and Literature Review
Cyclophosphamide for interstitial lung disease-associated acute respiratory failure: mortality, clinical response and radiological characteristics
Combination therapy with rituximab, low-dose cyclophosphamide, and prednisone for idiopathic membranous nephropathy: a case series
Interstitial lung disease associated with systemic sclerosis (SSc-ILD)
Phase 1 study of everolimus and low-dose oral cyclophosphamide in patients with metastatic renal cell carcinoma